HRMY
HRMY
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
20
$290.98M
Total Volume
$290.98M
41 transactions
Net Activity
$290.98M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Marshman Fund Trust II
10%
$139.39M total
Valor IV Pharma Holdings, LLC
10%
$139.39M total
Kapadia Sandip
CFO
$3.89M total
Dierks Jeffrey
CHIEF COMMERCIAL OFFICER
$3.38M total
Budur Kumar
CHIEF MEDICAL OFFICER
$3.11M total
Quick Actions
HRMY has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at HRMY (HRMY) engaged in a total of 41 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 20 were sales. The total volume of insider trading reached $290.98M.
The net insider activity for HRMY shows a net selling bias of $290.98M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Marshman Fund Trust II (10%), who traded 4.60M shares valued at $139.39M on Nov 1, 2024.
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts
HRMY - Harmony Biosciences Holdings Inc Stock Price and Quote
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
There May Be Reason For Hope In Harmony Biosciences Holdings' (NASDAQ:HRMY) Disappointing Earnings
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
symbol__ Stock Quote Price and Forecast
FAQs About HRMY Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for HRMY.